1. Home
  2. NBIX vs SUZ Comparison

NBIX vs SUZ Comparison

Compare NBIX & SUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

N/A

Current Price

$152.72

Market Cap

13.2B

Sector

Health Care

ML Signal

N/A

Logo Suzano S.A.

SUZ

Suzano S.A.

N/A

Current Price

$8.12

Market Cap

10.8B

ML Signal

N/A

Company Overview

Basic Information
Metric
NBIX
SUZ
Founded
1992
1924
Country
United States
Brazil
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Paper
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
13.2B
10.8B
IPO Year
1996
2002

Fundamental Metrics

Financial Performance
Metric
NBIX
SUZ
Price
$152.72
$8.12
Analyst Decision
Strong Buy
Analyst Count
22
0
Target Price
$180.91
N/A
AVG Volume (30 Days)
1.4M
2.7M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
2.15%
EPS Growth
41.95
N/A
EPS
3.30
N/A
Revenue
$161,626,000.00
N/A
Revenue This Year
$24.73
$13.28
Revenue Next Year
$13.14
$13.57
P/E Ratio
$45.72
$5.58
Revenue Growth
977.51
N/A
52 Week Low
$122.14
$7.56
52 Week High
$186.12
$11.54

Technical Indicators

Market Signals
Indicator
NBIX
SUZ
Relative Strength Index (RSI) 34.68 47.16
Support Level $125.85 $8.01
Resistance Level $160.08 $8.61
Average True Range (ATR) 6.42 0.21
MACD -2.47 -0.04
Stochastic Oscillator 9.54 41.39

Price Performance

Historical Comparison
NBIX
SUZ

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

About SUZ Suzano S.A.

Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.

Share on Social Networks: